Bremelanotide

N/A

Report date: 2025/11/03 20:01:55
NMEFirst In Class

Base Information

Drug NameBremelanotide
Drug Alias Name雌性激素肽Bremelanotidum布雷默浪丹Bremelanotida布美诺肽 +[9] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionMelanocortin receptor agonists
TargetsMelanocortin receptor
Therapy Area/IndicationsSexual Dysfunctions, PsychologicalNauseaObesity +[6] 
Global Approved IndicationsSexual Dysfunctions, Psychological
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/06/21
Country/TerritoryMainland China(BOAO LECHENG)CanadaUnited States +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesAmag Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCosette Pharmaceuticals IncPalatin Technologies IncKwang Dong Pharmaceutical Co Ltd +[4] 
Inactive CompaniesAmag Pharmaceuticals IncCatalent Belgium Sa
Active IndicationsSexual Dysfunctions, PsychologicalObesityKidney Diseases +[4] 
Inactive IndicationsNauseaSexual Dysfunction, Physiological

Other Information

ATC CodeGG02CX05
Related LinksWikipediaDrugBankKEGG